IQVIA Holdings Inc. IQV
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, IQVIA Holdings Inc. gets an algorithmic score of 49/100. It trades at 268.99 $, with a bullish technical trend (RSI 58.4) and 41.0% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (22.8%): generates strong profit on equity.
Weaknesses
- High leverage (debt/equity 258%): rate-sensitive.
Fundamentals
| P/E | 33.46 |
| Forward P/E | 18.59 |
| PEG | 0.97 |
| P/B | 7.17 |
| EV/EBITDA | 19.22 |
| P/S | 2.61 |
| ROE % | 22.82 |
| ROA % | 5.06 |
| Gross margin % | 32.97 |
| Operating margin % | 13.03 |
| Net margin % | 8.10 |
| Revenue growth % (y/y) | 8.70 |
| Earnings growth % (y/y) | -0.60 |
| Revenue CAGR % | 4.21 |
| Earnings CAGR % | 7.62 |
| Debt/Equity % | 257.98 |
| Current ratio | 0.71 |
| FCF yield % | 4.63 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | +2.8 % |
| 3 months | +39.2 % |
| 6 months | +61.9 % |
| YTD | +19.4 % |
| 1 year | +49.8 % |
| 3 years | +35.3 % |
| 5 years | +5.0 % |
Risk
| 1-year volatility | 41.0 % |
| Beta | 1.05 |
| 5-year max drawdown | -51.5 % |
| Sharpe 1A | 1.09 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.